By refining our understanding of CD71’s involvement in cancer and chronic disease, and by developing tailored therapeutic strategies that address both tumor growth and the health of other organ systems, we can improve patient outcomes and advance integrated disease management. This evidence concerns the gene TFRC and neoplasm.